Anti-beta-Amyloid Precursor Protein (APP)

Senile plaques and neurofibrillary tangles in brain are hallmarks of Alzheimer's disease. Mutations in the beta-amyloid precursor protein (beta-APP) are contributory factors to Familial Alzheimer's Disease. The primary constituent of senile plaques are deposits of the 4 kD amyloid beta-peptide, derived from amyloid beta-precursor proteins by internal proteolysis. The major brain beta-APP isoforms (APP695, 751, 770) are integral membrane proteins with a single large N-terminal extracellular domain, a single transmembrane domain, and a small cytoplasmic C-terminal tail. In the early 1990s, it was discovered that beta-APP is a useful marker for axonal injury. beta-APP is carried by fast anterograde transport vesicles to distal sites in the axon with the beta-APP C-terminus residing in the cytoplasm and the N-terminus in the vesicle. Upon axonal injury, beta-APP will pool in areas of impaired transport. beta-APP has been used as a marker of axonal injury in many studies of different pathologies, including: head trauma, HTLV-I-associated myelopathy, multiple sclerosis, shaken baby syndrome, and encephalomyelitis among others. Applications: Suitable for use in ELISA, Western Blot, Immunofluorscence and Immunoprecipitation. Other applications have not been tested. Recommended Dilution: ELISA: 0.1-1ug/ml, Western Blot: 0.2-2ug/ml, Immunofluoresence: 1-5ug/ml, Immunohistochemistry: 0.1-1ug/ml, Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.